98%
921
2 minutes
20
The concept of intravascular immunity is reshaping our understanding of immune surveillance, challenging the traditional view that immune responses are confined to either tissue parenchyma or the bloodstream. Our pilot study utilized intravascular staining (ivs) in rhesus macaques (RhM) to spatially distinguish pulmonary vasculature-associated (ivs+) CD8 T cells from interstitial (ivs-) T cells. Single-cell RNA sequencing and flow cytometry revealed that ivs+ T cells are not passive blood contaminants but rather a distinct, "resident-like" population enriched in cytotoxic effectors, with elevated expression of transcripts associated with tissue residency, cell adhesion, and vascular/platelet interactions, while ivs- T cells exhibited a classic T signature. The presence of SIV-specific tetramer+ ivs+ CD8 T cells in infected RhM suggests a role in antiviral defense within the lung vasculature. These findings provide new insight into intravascular immunity, highlighting a unique population of CD8 T cells as potential pulmonary vascular sentinels poised for rapid immune responses.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12182324 | PMC |
http://dx.doi.org/10.1016/j.isci.2025.112745 | DOI Listing |
Cancer Immunol Immunother
September 2025
Department of Thoracic Surgery, Tangdu Hospital, Fourth Military Medical University, Xi'an, 710038, China.
Objective: CircRNAs are involved in cancer progression. However, their role in immune escape in non-small cell lung cancer (NSCLC) remains poorly understood.
Methods: This study employed RIP-seq for the targeted enrichment of circRNAs, followed by Western blotting and RT-qPCR to confirm their expression.
Oncogene
September 2025
Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Pancreatic cancer is a highly aggressive malignancy with a dismal prognosis, characterized by a complex tumor microenvironment that promotes immunosuppression and limits the efficacy of immune checkpoint blockade (ICB) therapy. Fibroblast activation protein (FAP) is overexpressed in the tumor stroma and represents a promising target for therapeutic intervention. Here, we developed a novel antibody-drug conjugate (ADC) targeting FAP, and investigated its anti-tumor activity and ability to enhance ICB efficacy in pancreatic cancer.
View Article and Find Full Text PDFJ Cutan Pathol
September 2025
Division of Dermatology, Department of Medicine of Sensory and Motor Organs, Faculty of Medicine, Tottori University Faculty of Medicine, Yonago, Japan.
J Immunother Cancer
September 2025
Harold C Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Dallas, Texas, USA
Background: While highly efficacious for numerous cancers, immune checkpoint inhibitors (ICIs) can cause unpredictable and potentially severe immune-related adverse events (irAEs), underscoring the need to understand irAE biology.
Methods: We used a multidimensional approach incorporating single-cell RNA sequencing, mass cytometry, multiplex cytokine assay, and antinuclear antibody (ANA) profiling to characterize the peripheral immune landscape of patients receiving ICI therapy according to irAE development.
Results: Analysis of 162 patients revealed that individuals who developed clinically significant irAEs exhibited a baseline proinflammatory, autoimmune-like state characterized by a significantly higher abundance of CD57 T and natural killer (NK) T cells, plasmablasts, proliferating and activated CXCR3 lymphocytes, CD8 effector and terminal effector memory T cells, along with reduced NK cells and elevated plasma ANA levels.
J Immunother Cancer
September 2025
National Engineering Laboratory for Internet Medical Systems and Applications, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Background: Improving the efficacy of anti-programmed death 1 (PD-1) monoclonal antibody (mAb) therapy remains a major challenge for cancer immunotherapy in non-small cell lung cancer (NSCLC). Gut microbial metabolites can influence immunotherapy efficacy.
Methods: ELISA was used to compare the serum 5-hydroxyindoleacetic acid (5-HIAA) level in patients with NSCLC.